Mammoth Biosciences vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mammoth Biosciences is a CRISPR gene editing company co-founded by Nobel laureate Jennifer Doudna; pioneered NanoCas — the first efficient ultracompact extrahepatic gene editor; partnered with Regeneron for in vivo gene editing.
About
Mammoth Biosciences is a biotechnology company founded in 2017 by CRISPR pioneer and Nobel laureate Jennifer Doudna alongside Trevor Martin, Janice Chen, and Lucas Harrington. Headquartered in Brisbane, California, Mammoth focuses on developing ultracompact CRISPR systems that can be delivered in vivo using a single adeno-associated viral (AAV) vector — overcoming a major limitation of Cas9-based gene editors that are too large for efficient AAV delivery.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.